Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL401048 | 1.00 | SMN1; SMN2 (0.42) | SMN1; SMN2KMT2ANPC1ALDH1A1LMNA | |
| SCHEMBL2255665 | 0.86 | — | — | |
| SCHEMBL405144 | 0.84 | SMN1; SMN2 (0.47) | SMN1; SMN2KMT2ANPC1ALDH1A1RAB9A | |
| SCHEMBL2872803 | 0.84 | SMN1; SMN2 (0.45) | SMN1; SMN2KMT2ANPC1ALDH1A1RAB9A | |
| SCHEMBL2872807 | 0.84 | SMN1; SMN2 (0.45) | SMN1; SMN2KMT2ANPC1ALDH1A1RAB9A | |
| SCHEMBL2255668 | 0.82 | — | — | |
| SCHEMBL1095740 | 0.82 | — | — | |
| SCHEMBL400419 | 0.81 | HPGD (0.41) | SMN1; SMN2 | |
| SCHEMBL1105606 | 0.81 | KMT2A (0.41) | SMN1; SMN2KMT2A | |
| SCHEMBL405112 | 0.79 | KMT2A (0.47) | SMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153843-B2 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2012-04-10 | — | — | US | disclosed |
| US-8101640-B2 | Antibacterial agents | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-20110172174-A1 | Antibacterial agents | NOVARTIS VACCINES AND DIAGNOSTICS INC. | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172174-A1 | Antibacterial agents | MRPL21, SI, PGLS | SMN1; SMN2 2296/4885KMT2A 4800/4885NPC1 371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.